VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SUPN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SUPNSupernus Pharmaceuticals, Inc.
$29.04$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSUPNEarnings History

SUPN logoSupernus Pharmaceuticals, Inc. (SUPN) Earnings History

Profitable

18 years of earnings data (2008–2025) · Positive TTM net income

TTM Net Income
$450M
● Profitable
TTM EPS (Diluted)
$3.69
Per share, diluted
YoY EPS Growth
+10833.3%
Excellent
Net Margin
16.9%
After-tax profitability
EPS Growth Rate (CAGR)
1Y+10833.3%
3YN/A
5YN/A
10Y+19.3%
Operating Margin21.4%
Gross Margin80.1%
Return on EquityN/A
Return on Assets16.6%
Record Annual Net Income$263MFY2018
Record Quarterly EPS$5.92Q4 2011
Consecutive Profitable Years2years
Q3 2026
Net Income$137M
EPS (Diluted)$1.12
YoY Growth+10833.3%Excellent
QoQ Growth+12.3%Strong

Loading earnings history...

Supernus Pharmaceuticals, Inc. (SUPN) Earnings Overview

As of November 18, 2026, Supernus Pharmaceuticals, Inc. (SUPN) reported trailing twelve-month net income of $450M, reflecting +10833.3% year-over-year growth. The company earned $3.69 per diluted share over the past four quarters, with a net profit margin of 16.9%.

Looking at the long-term picture, SUPN's historical earnings data spans multiple years. The company achieved its highest annual net income of $263M in fiscal 2018.

Supernus Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 80.1%, operating margin of 21.4%, and net margin of 16.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →

Compared to peers including PCRX ($38M net income, 1.0% margin), ACAD ($362M net income, 36.5% margin), INVA ($193M net income, 63.8% margin), SUPN has outperformed on profitability metrics. Compare SUPN vs PCRX →

SUPN Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
SUPN logoSUPNCurrent
$450M$3.6916.9%-+10833.3%—
PCRX logoPCRX
$38M$0.921.0%1.0%+107.4%
ACAD logoACAD
$362M$2.0636.5%39.9%+68.4%
INVA logoINVA
$193M$2.6863.8%29.1%+816.7%
PRGO logoPRGO
-$1.8B$-12.70-33.5%-39.3%-723.2%
LNTH logoLNTH
$270M$3.9515.2%21.4%-21.8%
Best in group
Lowest in group

SUPN Historical Earnings Data (2008–2025)

18 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$210M+10400.0%$265M$1.6416.9%21.4%
2024$2M+101.6%$32M$0.010.2%2.7%
2023-$129M-193.2%-$156M$-0.91-11.8%-14.3%
2022-$44M-121.5%-$81M$-0.37-4.9%-9.0%
2021$205M+238.5%$213M$1.3125.9%26.9%
2020-$148M-210.4%-$156M$-1.08-22.9%-24.1%
2019$134M-49.0%$178M$0.9217.1%22.7%
2018$263M+331.1%$317M$1.7527.4%33.0%
2017$61M+90.1%$423M$0.415.3%36.9%
2016$32M+128.7%$338M$0.223.3%34.9%
2015$14M-29.5%$18M$0.289.7%12.2%
2014$20M+121.5%$24M$0.3216.3%19.9%
2013-$92M-99.4%-$62M$-2.90-767.7%-515.2%
2012-$46M-182.6%-$42M$-2.65-3127.3%-2849.3%
2011$56M+245.6%-$38M$3.646974.2%-4701.4%
2010-$38M-8461.5%-$40M$-2.78-36285.8%-37851.9%
2009$460,000+101.4%$4M$-0.211.2%10.6%
2008-$33M--$26M$-2.42-376.7%-290.9%

Download Data

Export SUPN earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open SUPN Terminal

SUPN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

18+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SUPN — Frequently Asked Questions

Quick answers to the most common questions about buying SUPN stock.

What is SUPN earnings per share (EPS)?

SUPN trailing twelve-month (TTM) diluted EPS is $3.69, reflecting +10833.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.

What is Supernus Pharmaceuticals, Inc.'s net income?

Supernus Pharmaceuticals, Inc. (SUPN) trailing twelve-month net income is $450M as of 2025. Earnings grew +10833.3% year-over-year. Supernus Pharmaceuticals, Inc. has been profitable for 2 consecutive years.

Is SUPN profitable?

Yes, SUPN is profitable with a TTM net income of $450M and a net profit margin of +16.9%. Supernus Pharmaceuticals, Inc. has generated profits for 2 consecutive years.

What is SUPN's earnings growth rate?

SUPN compound annual EPS growth rates (CAGR): 1-Year: +10833.3%, 3-Year: N/A, 5-Year: N/A, 10-Year: +19.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.

What are SUPN's profit margins?

Supernus Pharmaceuticals, Inc. net profit margin is +16.9%, operating margin is +21.4%, and gross margin is +80.1%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.

Is SUPN growing earnings?

Yes, SUPN earnings are accelerating — EPS growth of +10833.3% exceeds the 5-year CAGR of N/A. TTM net income reached $450M. Earnings momentum is strengthening.

What was SUPN's best earnings year?

Supernus Pharmaceuticals, Inc.'s highest annual net income on record is $263M, achieved in fiscal year 2018. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.

What were SUPN's earnings last quarter?

SUPN's most recent reported quarter was Q3 2026. Net income was $137M with diluted EPS of $1.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.

SUPN Earnings Over Time (2008–2025)

Net income & EPS — annual and quarterly view